英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
monoth查看　monoth　在百度字典中的解释百度英翻中〔查看〕
monoth查看　monoth　在Google字典中的解释Google英翻中〔查看〕
monoth查看　monoth　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • POLARIS-AD Phase 3 Trial of PDE5 Inhibitor AR1001 Completes Treatment . . .
    The global phase 3 registration trial enrolled 1535 patients across 240 sites and has completed its 52-week double-blind treatment phase, with no unexpected safety signals observed, even in participants on concomitant antiamyloid therapies
  • Study Details | NCT05531526 | Phase 3, Double-blind, Randomized . . .
    A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 Over 52 Weeks in Participants With Early Alzheimer's Disease (Polaris-AD)
  • Program | Clinical Trials on Alzheimer’s Disease
    CTAD 2026 will feature significant clinical trial readouts, including Phase 3 results from POLARIS-AD (AR1001), Phase 2a proof-of-concept data on NTRX-07 targeting neuroinflammation, and topline results from the Phase 2b PRImus-AD trial (PRI-002) in early AD
  • POLARIS-AD | VJDementia
    Mirodenafil in early Alzheimer’s disease: updates from the Phase III POLARIS-AD trial Sharon Sha • 27 Mar 2026 1:37 Update on the ongoing Phase III POLARIS-AD trial of mirodenafil in MCI or mild dementia due to AD Sharon Sha • 17 Dec 2025
  • POLARIS-AD - Alzheimer Europe
    After the initial 52-week treatment phase, all participants can then enter an extension phase of 52 weeks and receive AR1001 (30 mg) daily What your involvement will entail? During the study, participants will have to undergo brain scan or lumbar puncture (CSF)
  • AriBio Completes Treatment Phase of Global Phase 3 POLARIS-AD Trial of . . .
    POLARIS-AD enrolled 1,535 patients with early Alzheimer’s disease across approximately 230 clinical trial sites in 13 countries, including the United States, Europe, South Korea, and China The study was conducted according to the planned protocol and timeline, with 1,348 participants completing the 52-week dosing by the end of June 2026
  • NCT05531526: Phase 3, Double-blind, Randomized, Placebo-controlled . . .
    This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety of AR1001 for the treatment of participants with early AD
  • POLARIS-AD Trial - Factually
    A global, randomized 52-week Phase 3 trial of over 1,500 participants for MCI or mild AD, testing AR1001 (mirodenafil)
  • Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate . . .
    This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety of AR1001 for the treatment of participants with early AD
  • AriBio to present AR1001 phase 3 results at CTAD 2026 in Boston
    AriBio will present efficacy and safety results from the global phase 3 POLARIS-AD trial of its oral Alzheimer’s disease candidate AR1001 at CTAD 2026 in Boston on Nov 16





中文字典-英文字典  2005-2009